-
CME/CE
Common Over-the-Counter Analgesics May Increase Hypertension Risk in Older Men
A study adds further support to the hypothesis that popular everyday painkillers, such as aspirin, acetaminophen, and ibuprofen, increase the risk of developing hypertension.
Medscape Medical News, February 2007
-
MEDAL: Are the GI Benefits of Etoricoxib Worthwhile?
Detailed gastrointestinal results from the trial, comparing Merck’s new COX-2 inhibitor etoricoxib with diclofenac, show significantly fewer uncomplicated upper-gastrointestinal clinical events with etoricoxib, but no difference in complicated GI events, leading to questions about whether this benefit is clinically relevant.
Heartwire, February 2007
-
CME/CE
Celecoxib Therapy Does Not Increase Cardiovascular Events
A patient-level meta-analysis failed to show that risk for myocardial infarction, stroke, or death was higher with celecoxib than with placebo or nonselective NSAIDs.
Medscape Medical News, January 2007
-
Coxibs May Have Less Risk for Upper GI Bleeding Than Nonselective NSAIDs or Aspirin
A case-controlled study also suggests that when combined with low-dose aspirin, the differences between nonselective NSAIDs and coxibs tend to disappear.
Medscape Medical News, December 2006
-
FDA Safety Changes: Prevacid NapraPAC, Epzicom, Forane
The FDA has approved revisions to the safety labeling for lansoprazole and naproxen, abacavir sulfate/lamivudine, and isoflurane volatile liquid.
Medscape Medical News, November 2006
-
MEDAL: Etoricoxib Shows Same Thrombotic Cardiovascular Risk as Diclofenac
Both drugs were similar in effectiveness against arthritis symptoms, but diclofenac was associated with more upper-GI and hepatic events, whereas etoricoxib showed more heart failure and discontinuations due to edema and hypertension. Discussion is focusing on whether diclofenac was the appropriate comparator drug, as it is also believed to carry an increased cardiovascular risk.
Heartwire, November 2006
-
Meta-analysis Linked Rofecoxib, Not Other COX-2 Inhibitors, With Renal Harm
A meta-analysis of randomized trials of cyclooxygenase-2 inhibitors found that rofecoxib was uniquely associated with greater risk for renal events.
Medscape Medical News, September 2006
-
COX-2 Inhibitors and NSAIDs Have Cardiotoxic Effects
The findings from a review of observational studies suggest that diclofenac, indomethacin, and meloxicam increase cardiovascular risk as much as rofecoxib and that naproxen has a neutral effect.
Medscape Medical News, September 2006
-
Recalls & Warnings Ibuprofen May Reduce Protective Effects of Aspirin
According to the FDA, patients should be instructed on the appropriate timing of ibuprofen dosing if they are also taking aspirin for cardioprotective effects.
Medscape Medical News, September 2006
-
Celecoxib Reduces Colorectal Adenomas, but CV Risk Remains High
Two trials found that celecoxib continues to show promise in colorectal cancer, but heart risks must be monitored.
Medscape Medical News, August 2006
-
Short-term Use of Rofecoxib May Increase Cardiovascular Risk
A correction notice was issued regarding APPROVe, and an additional analysis reports an increased risk for confirmed thrombotic events associated even with short-term use of rofecoxib.
Medscape Medical News, June 2006
-
New England Journal of Medicine Corrects Vioxx Data, and Experts Warn of Risks with Similar Drugs
Editors report the trial that prompted Merck to pull the popular COX-2 inhibitor off the market had important errors — problems that could crop up with similar drugs, if investigators are not vigilant.
Medscape Medical News, June 2006
-
Anti-inflammatory Drugs Increase Mortality After Previous Myocardial Infarction
Cyclooxygenase-2 inhibitors in all dosages and nonselective NSAIDs in high dosages should be used with particular caution after acute myocardial infarction.
Medscape Medical News, June 2006
-
Therapies for Reducing Gastric Acid Linked to Increased Risk of Clostridium difficile
Both proton pump inhibitors and histamine 2 receptor antagonists are associated with a greater likelihood of CDAD.
Medscape Medical News, December 2005
-
FDA Safety Labeling Changes: Striant, Naprosyn, EC-Naprosyn, Anaprox, Anaprox DS, AndroGel
The FDA has approved revisions to the safety labeling for a testosterone buccal system (Striant mucoadhesive); naproxen suspension/tablets (Naprosyn) and enteric-coated delayed-release tablets (EC-Naprosyn); naproxen sodium regular and double-strength tablets (Anaprox, Anaprox DS); and testosterone gel, 1% (AndroGel).
Medscape Medical News, February 2005
-
NSAIDs Still Under Surveillance -- Celecoxib, Valdecoxib, and Naproxen Have Been Added to the List of Suspects
In the wake of Vioxx's notorious publicity, researchers, regulators, and clinicians are now putting Celebrex, Bextra, and the entire class of COX-2 inhibitors under the microscope.
Medscape Cardiology, January 2005
-
Merck's Withdrawal of Vioxx Calls the Cardiac Safety of COX-2 Inhibitors Into Question
Are the cardiovascular risks posed by Vioxx applicable to all COX-2 inhibitors? How prolific is the problem, and did the FDA do enough?
Medscape Cardiology, November 2004
